Who are P2Y12 antagonist monotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ticlid, bivalirudin + clopidogrel + aspirin, Clopidogrel, cilostazol, Clopidogrel only, aspirin + clopidogrel + celecoxib, OAC + clopicogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/p2y12-antagonist-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

P2Y12 antagonist monotherapy — Competitive Intelligence Brief

P2Y12 antagonist monotherapy (P2Y12 antagonist monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist. Area: Cardiovascular.

marketed P2Y12 receptor antagonist P2Y12 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

P2Y12 antagonist monotherapy (P2Y12 antagonist monotherapy) — Samsung Medical Center. P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
P2Y12 antagonist monotherapy TARGET	P2Y12 antagonist monotherapy	Samsung Medical Center	marketed	P2Y12 receptor antagonist	P2Y12
Ticlid	TICLOPIDINE		marketed	ADP receptor antagonist	P2Y12	1991-01-01
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
Clopidogrel only	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist class)

First Affiliated Hospital of Harbin Medical University · 4 drugs in this class
Fu Wai Hospital, Beijing, China · 1 drug in this class
Ping-Yen Liu · 1 drug in this class
Samsung Medical Center · 1 drug in this class
St. Antonius Hospital · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). P2Y12 antagonist monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/p2y12-antagonist-monotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab